Literature DB >> 7729451

Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia.

M Arning1, A H Heer-Sonderhoff, A Wehmeier, W Schneider.   

Abstract

Pulmonary toxicity with acute dyspnea occurred during infusion of a liposomal amphotericin B preparation (AmBisome) in two adult leukemic patients. The preparation was administered as a one hour infusion at a dose of 3 mg/kg body weight. Within 15 min after starting the infusion, both patients experienced sudden onset of dyspnea and chest tightness. Physical examination showed the patients to be anxious and restless with tachycardia and orthopnea but without other cardiopulmonary findings. No elevation of body temperature, rigors or chills were recorded. Symptoms disappeared within minutes after discontinuing the infusion. At present, the pathophysiologic mechanisms underlying these side effects are unknown.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729451     DOI: 10.1007/bf02112616

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

1.  Cardiopulmonary toxicity after liposomal amphotericin B infusion.

Authors:  S J Levine; T J Walsh; A Martinez; P Q Eichacker; G Lopez-Berestein; C Natanson
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

2.  Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep.

Authors:  K Miyamoto; E Schultz; T Heath; M D Mitchell; K H Albertine; N C Staub
Journal:  J Appl Physiol (1985)       Date:  1988-03

3.  Effect of infusion rate on amphotericin B-associated febrile reactions.

Authors:  J D Cleary; D Weisdorf; C V Fletcher
Journal:  Drug Intell Clin Pharm       Date:  1988-10

4.  Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients.

Authors:  J Tollemar; O Ringdén; S Andersson; B Sundberg; P Ljungman; E Sparrelid; G Tydén
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

5.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Authors:  F Meunier; H G Prentice; O Ringdén
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

  5 in total
  6 in total

Review 1.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

2.  Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Authors:  T J Walsh; V Yeldandi; M McEvoy; C Gonzalez; S Chanock; A Freifeld; N I Seibel; P O Whitcomb; P Jarosinski; G Boswell; I Bekersky; A Alak; D Buell; J Barret; W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 3.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.

Authors:  P Schöffski; M Freund; R Wunder; D Petersen; C H Köhne; H Hecker; U Schubert; A Ganser
Journal:  BMJ       Date:  1998-08-08

Review 5.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

Review 6.  Immunological and Toxicological Considerations for the Design of Liposomes.

Authors:  Collin T Inglut; Aaron J Sorrin; Thilinie Kuruppu; Shruti Vig; Julia Cicalo; Haroon Ahmad; Huang-Chiao Huang
Journal:  Nanomaterials (Basel)       Date:  2020-01-22       Impact factor: 5.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.